

#4  
3.3.99  
RP

Patent  
Attorney's Docket No. 029395-005

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	
Jean-Luc IMLER et al.	)	Group Art Unit: Unassigned
Application No.: Unassigned	)	Examiner: Unassigned
Filed: December 22, 1998	)	
For: DEFECTIVE ADENOVIRUSES AND	)	
CORRESPONDING	)	
COMPLEMENTATION LINES	)	

Jc549 U.S. PTO  
09/218143  
12/22/98

**INFORMATION DISCLOSURE STATEMENT  
TRANSMITTAL LETTER**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$240.00 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e), a petition requesting consideration of the information disclosure statement, and the petition fee of \$130.00 as set forth in 37 C.F.R. § 1.17(i) are also enclosed.
- ☐ Charge \$\_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \$\_\_\_\_\_ is enclosed for the fee due.

Information Disclosure Statement Transmittal Letter

Application Serial No. Unassigned

Attorney's Docket No. 029395-005

Page 2

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in triplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: \_\_\_\_\_

  
Susan M. Dadio

Registration No. 40,373

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: December 22, 1998

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of )  
 )  
Jean-Luc IMLER et al. )  
 )  
Application No.: Unassigned ) Group Art Unit: Unassigned  
 )  
Filed: December 22, 1998 ) Examiner: Unassigned  
 )  
For: DEFECTIVE ADENOVIRUSES AND )  
CORRESPONDING )  
COMPLEMENTATION LINES )

jc549 U.S. PTO  
09/218143  
12/22/98

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited below, except for U.S. Patent No. 5,700,470, were submitted or referenced in parent Application Serial No. 08/379,452. Thus, these documents are not enclosed herewith. However, a copy of U.S. Patent No. 5,700,470 is enclosed.

**U.S. PATENTS**

1. U.S. Patent No. 5,670,488, issued September 23, 1997.
2. U.S. Patent No. 4,920,209, issued April 24, 1990.
3. U.S. Patent No. 5,700,470, issued December 23, 1997.

**FOREIGN PATENTS**

4. International Publication No. WO 94/12649, published June 9, 1994.
5. International Publication No. WO 93/19191, published September 30, 1993.

**OTHER DOCUMENTS**


6. LaFont et al., Lancet, 346:1442-1443 (1995).
7. Marshall, Science, 269:1050-1055 (1995).
8. Miller et al., FASEBJ, 9:190-199 (1995).
9. Culver et al., TIG, 10(5):174-178 (1994).
10. Hodgson, Exp. Opin. Ther. Pat., 5(5):459-468 (1995).
11. Berkner et al., Biotechniques, 6(7):616-628 (1988).
12. Weinberg et al., Proc. Nat. Acad. Sci., 80:5383-5386 (1993).
13. Bajocchi et al., Nature Genetics, 3:229-234 (1993).
14. James et al., Antiviral Chem. Chemo., 2(4):191-214 (1991).
15. L.E. Babiss, Journal of Virology, 63(6):2709-2717 (1989).
16. Statford-Perricaudet et al., Human Gene Transfer, 219:51-61 (1991).
17. M.A. Rosenfeld et al., Cell, 68(1):143-155 (1992).
18. J.L. Imler et al., Gene Therapy, 3:75-84 (1996).
19. Gabriel Bellon et al., Human Gene Therapy, 8:15-25 (1997).

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

To assist the Examiner, the above-cited documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialled copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:   
Susan M. Dadio  
Registration No. 40,373

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: December 22, 1998